HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a Buy rating on Halozyme Therapeutics (NASDAQ: HALO) and raised the price target from $115 to $130.